{"id":1629,"date":"2015-06-29T15:24:30","date_gmt":"2015-06-29T19:24:30","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=1629"},"modified":"2015-07-08T02:16:48","modified_gmt":"2015-07-08T06:16:48","slug":"nitrofurantoin-an-old-drug-resurrected-needs-prospective-scrutiny","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2015\/06\/29\/1629\/nitrofurantoin-an-old-drug-resurrected-needs-prospective-scrutiny\/","title":{"rendered":"Nitrofurantoin \u2013 An Old Drug Resurrected Needs Prospective Scrutiny"},"content":{"rendered":"

\"UTI<\/a>When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty.<\/p>\n

Often, older drugs were approved based on rather limited\u00a0data, often considered incomplete by today\u2019s standards.\u00a0 Take colistin as an example: approved in the early 60ies, we still don\u2019t know how to dose the drug properly for efficacy and safety.<\/p>\n

\"fimbriated<\/a>
Piliated E. coli with MS fimbriae<\/figcaption><\/figure>\n

Older drugs also often carry the mantle of safety because studies were never performed that would have shown issues.\u00a0 Take erythromycin as an example: touted as one of the safest antibiotics, it is now known to have enormous potential for QT prolongation.\u00a0 Especially the IV form \u2013 fortunately rarely used \u2013 has been associated with QTc prolongation of >40 msec.\u00a0 There is plenty of documentation showing that Torsade de Pointes (TdP) ventricular arrhythmia\u00a0is not uncommon.<\/p>\n

Older drugs don\u2019t have a sponsor interested in investing in new studies.\u00a0 Hence, when we resort to a colistin, fosfomycin, or nitrofurantoin after a long hiatus of infrequent use, we get confronted with adverse events long forgotten, labeling restrictions without clear scientific basis and the need for updated sensitivity data and new breakpoint assessments.<\/p>\n

All these issues are now encountered with nitrofurantoin, a drug with a long history of use for uncomplicated UTI\u00a0but sidelined by amoxicillin, then TMP\/SMX, and later by the quinolone family of drugs.\u00a0 Since E. coli have become resistant to all 3 antibiotic classes in recent years, the latest\u00a0guidelines encourage us to use of nitrofurantoin as a first line agent for this indication.<\/p>\n

The efficacy of nitrofurantoin against uropathogenic E. coli is considered en par with TMP\/SMX or cephalosporins according to a recent Cochrane analysis[1]<\/a>.\u00a0 While this is good news, it is also old news as most of these comparative trials were done in the 90ies. \u00a0Fortunately, most uropathogens are susceptible: \u00a0In a large US outpatient study, urinary E.coli were mostly\u00a0susceptible to nitrofurantoin except for a subset of highly MDR isolates.[2]<\/a> \u00a0\u00a0Likewise, the efficacy of nitrofurantoin in ESBL E. coli was unreliable, with resistance in 29% of isolates[3]<\/a>.\u00a0 In UK isolates of CRE, nitrofurantoin MICs were high and most isolates tested resistant.[4]<\/a>\u00a0\u00a0As would be expected, such resistance is by no means\u00a0universal and evenly distributed.<\/p>\n

Regarding safety, nitrofurantoin is not a placebo. Case reports of idiosyncratic reactions, both hepatic and pulmonary, have been published by us\u00a0[5]<\/a> and other authors but are fortunately rare.\u00a0 The disease is often characterized as a hypersensitivity pneumonitis or hepatitis, not always reversible and sometimes\u00a0chronic. The main concern is that it may not be recognized as a drug reaction and the connection to nitrofurantoin may not be made in time.<\/p>\n

Then there are GI side effects which we often consider as tolerability, not as safety issues.\u00a0 Nonetheless, nausea and vomiting are\u00a0frequent (30%) and may lead to premature discontinuation. \u00a0Interestingly, this is a direct drug effect on the emetic brain stem center.[6]<\/a><\/p>\n

When data is missing, or incomplete, when dossiers are old and partially irrelevant, no wonder that it becomes difficult to reconstruct even some pieces that made it into the Package Label.\u00a0 Oplinger was unable to find substantiation for the cut-off and contraindication for patients with\u00a0Clcr < 50 ml\/min. Concerns about\u00a0systemic accumulation of the drug or its nitro metabolites may have led to this restriction.[7]<\/a><\/p>\n

In this day and age when MDR pathogens are even found in an outpatient setting, we are going back to colistin, nitrofurantoin, fosfomycin \u2013 drugs for which we have much fewer scientific data than anything approved in the last 25 years.<\/p>\n

Welcome to our Brave New World. \u00a0Admittedly, the old drugs worked well against the old bugs, but now we have to see how good they are for our present assortment of bugs and super-bugs.<\/p>\n

It would be nice to have some new antibiotics to get us Back to the Future.<\/p>\n

References:
\n<\/strong>[1]<\/a> Zalmanovici Trestioreanu A.\u00a0 Antimicrobial agents for treating uncomplicated urinary tract infection in women (Review). The Cochrane Library 2010, Issue 10, 2010
\n[2]<\/a> G Sanchez.\u00a0 J Antimicrob Chemother. 2014;69: 3259
\n[3]<\/a> Puerto A. Diagn Microbiol Infect Dis 2006; 54: 135
\n[4]<\/a> D Livermore.\u00a0 Internat J Antimicrob Agents 37; 2011: 415
\n[5]<\/a> H Reinhart.\u00a0 Gastroenterology. 1992;102 (4 Pt 1):1396
\n[6]<\/a> D Greenwood.\u00a0 In Finch: Antibiotic and Chemotherapy, Chapter 31, 356
\n[7]<\/a> M Oplinger.\u00a0 Ann Pharmacother. 2013;47:106<\/p>\n","protected":false},"excerpt":{"rendered":"

When older drugs get reintroduced into clinical practice because pathogens have developed resistance to newer agents, it comes at the price of uncertainty. Often, older drugs were approved based on rather limited\u00a0data, often considered incomplete by today\u2019s standards.\u00a0 Take colistin as an example: approved in the early 60ies, we still Continue reading Nitrofurantoin \u2013 An Old Drug Resurrected Needs Prospective Scrutiny<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":1635,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[3,18],"tags":[725,403,11,177,958,363,221,350,509,898,1105,1099,1104,1098,1103,1102,1106,1107,767,1108,1101,1100,1097,1110,1109],"class_list":["post-1629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the_news","category-the_viewpoint","tag-amoxicillin","tag-antibiotic-blog","tag-cochrane","tag-colistin","tag-colistin-dosing","tag-cre","tag-erythromycin","tag-esbl","tag-fluoroquinolones","tag-fosfomycin","tag-incomplete-data","tag-macrodantin","tag-mdr-uropathogens","tag-nitrofurantoin","tag-nitrofurantoin-efficacy","tag-nitrofurantoin-safety","tag-qtc-prolongation","tag-tdp","tag-tmpsmx","tag-torsade-de-pointes","tag-uncomplicated-uti","tag-uropathogenic-e-coli","tag-uti-treatment-guidelines","tag-uuti","tag-ventricular-arrhythmia"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/06\/UTI-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-qh","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":4126,"url":"https:\/\/allphasepharma.com\/dir\/2025\/04\/03\/4126\/blujepa-gepotidacin-fda-approval-uuti-efficacious-e-coli-nitrofurantoin\/","url_meta":{"origin":1629,"position":0},"title":"BLUJEPA \/ Gepotidacin APPROVED FOR UNCOMPLICATED UTI – 1","author":"Harald","date":"April 3, 2025","format":false,"excerpt":"GSK\u2019s pipeline in anti-infectives is impressive. It comprises drugs for bacterial, mycobacterial, fungal, viral infections, and for malaria; in addition, they have a number of vaccines in development.\u00a0 Several antibiotics are listed on their website targeting UTI pathogens, and one of them was just approved, namely gepotidacin \/ Blujepa, a\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/04\/HR_Gepotidacin-in-uUTI-SLIDER.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/04\/HR_Gepotidacin-in-uUTI-SLIDER.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/04\/HR_Gepotidacin-in-uUTI-SLIDER.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":1401,"url":"https:\/\/allphasepharma.com\/dir\/2015\/04\/30\/1401\/a-renaissance-for-old-drugs-fosfomycin-and-colistin\/","url_meta":{"origin":1629,"position":1},"title":"A Renaissance for Old Drugs: Fosfomycin and Colistin","author":"Harald","date":"April 30, 2015","format":false,"excerpt":"Fosfomycin Who would have thought that a drug that has been around since 1969 [2] could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available in Europe for a quite some\u00a0time but not in the\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2095,"url":"https:\/\/allphasepharma.com\/dir\/2015\/11\/03\/2095\/amdac-november-5-2015-on-fluoroquinolones-in-as-aecb-uuti-part-1\/","url_meta":{"origin":1629,"position":2},"title":"AMDAC November 5, 2015 on Fluoroquinolones in ABS, ABECB, uUTI\u00a0 – Part 1","author":"Harald","date":"November 3, 2015","format":false,"excerpt":"Only now, a few days before the actual AMDAC meeting, the\u00a0FDA\u2019s Briefing Document becomes available to the public.\u00a0 The topic of the December 5th meeting:\u00a0 Reappraisal of the risk\/benefit of fluoroquinolones (FQ) in approved but \u201cmild, self-limiting\u201d disease indications in light of new post-approval safety issues. The document is 617\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"AMDAC - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2313,"url":"https:\/\/allphasepharma.com\/dir\/2016\/03\/03\/2313\/iv-fosfomycin-to-the-rescue-and-to-a-place-near-you\/","url_meta":{"origin":1629,"position":3},"title":"IV Fosfomycin To The Rescue \u2013 And To a Place Near You","author":"Harald","date":"March 3, 2016","format":false,"excerpt":"A recent letter to the Editor by Simkins et al. is worth reviewing [1]. The authors describe the complicated course of a patient who suffered graft rejection after liver transplantation, received broad-spectrum antibiotics during prolonged hospitalization and eventually had a bloodstream infection with carbapenem-resistant Klebsiella pneumoniae (CRKP) which was resistant\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Fosfomycin - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Fosfomycin-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Fosfomycin-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/Fosfomycin-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2112,"url":"https:\/\/allphasepharma.com\/dir\/2015\/11\/09\/2112\/the-fda-amdac-on-fluoroquinolones-part-2-where-were-the-fq-advocates\/","url_meta":{"origin":1629,"position":4},"title":"The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?","author":"Harald","date":"November 9, 2015","format":false,"excerpt":"Any FDA meeting is a high-stakes game for industry: \u00a0One never knows how the discussions will go. Some oddball issue may take center stage and usurp much time, creating an unbalanced perspective.\u00a0 At other times, simple issues seem to create controversy, questions are not properly understood in the context of\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"AMDAC Part 2 - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-Part-2-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-Part-2-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/11\/AMDAC-Part-2-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2186,"url":"https:\/\/allphasepharma.com\/dir\/2015\/12\/19\/2186\/aztreonam-plus-avibactam-a-new-bright-star-in-the-night-sky\/","url_meta":{"origin":1629,"position":5},"title":"Aztreonam PLUS Avibactam \u2013 A New Bright Star in the Night Sky","author":"Harald","date":"December 19, 2015","format":false,"excerpt":"Looking at the molecular structure of ceftazidime (CTAZ) and aztreonam (ATM), the differences are clear, and so are the similarities: ATM does not have the cephem ring structure of CTAZ, only the 4-member beta-lactam ring.\u00a0 However, the side chains are identical in both CTAZ and ATM which explains the overlapping\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Avibactam - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/12\/Avibactam-slider.jpg?resize=700%2C400 2x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=1629"}],"version-history":[{"count":6,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1629\/revisions"}],"predecessor-version":[{"id":1685,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1629\/revisions\/1685"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/1635"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=1629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=1629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=1629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}